Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Event Highlights

Preliminary Agenda Highlights

Fast-Track Your Antibody Research to the Clinic and Beyond

ENGINEERING AND APPLICATION OF THERAPEUTIC ANTIBODIES FOR NEURODEGENERATIVE DISEASES

Towards Development of Antibody Therapy for C9orf72 ALS/FTD

Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida


Altering APP Processing with a Proteolytic Diabody

Michael Sierks, Ph.D., Professor, Chemical Engineering, Arizona State University


Tau Immunotherapy

Peter Davies, Feinstein Institute for Medical Research, North Shore/LIJ Health System

PD Immunotherapy – A-Syn

Eliezer Masliah, M.D., Director, Division of Neurosciences, National Institutes of Aging, NIH


Antibody Therapy for Alzheimer’s Disease – Key Challenges

Christoph Hock, M.D., Professor and Director, Institute for Regenerative Medicine (IREM), University of Zurich and Co-Founder, Neurimmune, Switzerland

PRE-CONFERENCE EVENTS

PRE-CONFERENCE TRAINING COURSE

Monday, December 11, 2017, 9:00am-5:00pm

Introduction to Antibody Engineering

Instructor: David Bramhill, Ph.D., Bramhill Consulting, LLC and Research, Corporation Technologies

*Additional registration fee applies. See the pricing tier on page 8 or visit the website for more details

PRE-CONFERENCE WORKSHOPS

Workshop A: Selecting Antibodies against Cell-Surface Targets

Workshop Moderator: Andrew Bradbury, M.D., Ph.D., Research Scientist and Group Leader, Los Alamos National Laboratories

Workshop B: Developability of Antibodies

Workshop Moderator: Mark Chiu, Associate Director of Development, Janssen R&D

*Additional registration fee applies. See the pricing tier on page 8 or visit the website for more details.

KEYNOTE PRESENTATIONS

Deciphering the Human Immunome

James Crowe, MDDirector, Vanderbilt Vaccine Center, Vanderbilt University Medical Center

Ocrelizumab in Relapsing and Primary Progressive Multiple Sclerosis

Peter Chin, M.D., Group Medical Director, Neuroscience, SPECTRUM Medical Unit, US Medical Affairs, Genentech 

Paracrine Delivery

Andreas Plückthun, Ph.D. Professor and Director, Department of Biochemistry, University of Zurich

Biologic Discoveries Across the Blood-Brain Barrier with IgG Infusion Proteins

William Pardridge, MD, Distinguished Professor Emeritus / Founder and CSO, UCLA / ArmaGen

NOVEL ENGINEERING STRATEGIES TO ENHANCE ANTIBODY FUNCTIONS

From Format to Function - Transformative Antibody Therapeutics

Martin Steegmaier, Ph.D., Head of Discovery, Large Molecule Research, Roche pRED, Roche Innovation Center Munich, Germany

Agonizing the TNFR Superfamily for Cancer Immunotherapy

Greg Lazar, Ph.D., Director and Senior Scientist, Antibody Engineering, Genentech

Adapted Fc-glycan Changes for Enhanced ADCC and/or CDC

Gestur Vidarsson, Ph.D., Head of Immunoglobulin Research/PI, Experimental Immunohematology,    Sanquin Research, The Netherlands

BIOLOGICAL IMPACT OF FC RECEPTOR ENGAGEMENT

SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases

Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan

Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity

James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech


Antibody Optimization for Treg Depletion in Cancer Therapy

Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

Selective FcγR Engagement by Agonistic Anti-CD40 Abs

Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel

Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs

Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

ROLE OF POST-TRANSLATIONAL MODIFICATION IN ANTIBODY FUNCTION

Fc Fucosylation and Sialylation and Antibody Effector Function

Jeffrey Ravetch, Ph.D., Professor, Rockefeller University

Sulfation of Broadly Neutralizing HIV Antibodies

Raiees Andrabi, Research Associate, The Burton Lab,The Scripps Research InstitutePRELIMINARY AGENDA 

Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity

Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, The Netherlands

Post-translational Modification of Antibodies in Rheumatoid Arthritis

Leendert A. Trouw Ph.D., Assistant, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden,The Netherlands

Regulation of Autoantibody Activity by the IL-23–TH17 Axis and its Impact on Autoimmune Disease

Gerhard Krönke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany

IMMUNO-ONCOLOGY: CHECKPOINTS

SIMPLE Antibody™ Platform Generates Unique Species Cross-reactive Antibodies against Immune Checkpoints

Erik Hofman, Ph.D., Senior Scientist, Research Department, Argenx, Belgium 

Immuno-oncology and Prostate Cancer

Xin Lu, Professor M.D., University of Notre Dame

A Novel Cytokine Receptor Agonistic Antibody by Design

Cheng-I Wang, Ph.D., Senior Principal Investigator, Singapore Immunology Network, Biomedical Sciences Institutes, ASTAR, Singapore

Boosting Cancer Immunotherapy with Combined Immunomodulatory Drugs

Mickey Hu, Ph.D., Scientist, Panorama Institute of Molecular Medicine

Cow Ultralong CDR3 Antibodies Targeting Exhausted T-cells

Vaughn Smider M.D., Ph.D., Associate Professor, Molecular Medicine, The Scripps Research Institute

ANTIBODY BASED INNOVATIONS IN THE TUMOR MICROENVIRONMENT

Protia – Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment

Volker Schellenberger, Ph.D., CEO and President, Amunix

Immuno-Viral Therapy for Solid Tumors

Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics

Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics

Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members

Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus

mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies

Sebastian Kreiter, Head, Tron/BioNTech, Germany

An Update on the Darzalex Story

Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen

OVERCOMING DELIVERY CHALLENGES INCLUDING BRAIN AND INTRACELLULAR TARGETS

Bacterial Secretion Systems

Thomas Marlovits, Professor, Institute of Molecular Pathology, Austria

Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study

Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium

Bispecific Antibodies Targeting Transfer in Receptor or CD98 to Facilitate Delivery Across the Blood Brain Barrier

Jasi Atwal, Scientist, Genentech

Artificial Immunotoxins

Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, Germany

ANTIBODY-DRUG CONJUGATES & FUSION PROTEINS

Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity

Julian Spallholz, Ph.D., Professor, Nutritional Sciences,Texas Tech University

Antibody-Drug Conjugates for Treating Steroid-Resistant Malignancies and Autoimmune Diseases

Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics,National Cancer Center, Japan

Targeting Tumors and Their Vasculature with Antibody-Drug Conjugates

Dimiter Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH

Novel Calicheamicin Antibody-Drug Conjugates

Julia Gavrilyuk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx

NOVEL ANTIBODY DISPLAY, SELECTION AND SCREENING

Using Next Generation Sequencing in Antibody Libraries

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Quantitative Proteomics

Jim Wells, Professor, UCSF

Engineering Developable Antibodies

Peter Tessier, Professor, Rensselaer Polytechnic Institute

Programming Antibodies and Antigens using Deep Sequencing-Enabled Protein Engineering

Tim Whitehead, Ph.D., Associate Professor, Chemical Engineering and Materials Science, Michigan State University

Advances in Yeast Display Selections for Membrane Targets

Benjamin Hackel, Ph.D., Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota

Functional Interrogation and Mining of Natively Paired Heavy:Light Human Antibody Repertoires

Department of Pharmaceutical Chemistry, The University of Kansas

ROLE OF THE T-CELL REPERTOIRE IN CANCER, INFECTIOUS DISEASES AND AUTOIMMUNITY

Genetic Variation in MHC Proteins is Associated with T-cell Receptor Expression Biases

Eilon Sharon, Ph.D., Postdoctoral Fellow, Howard Hughes Medical Institute, Stanford University

CD8 T-cell Repertoire Dynamics and Their Association with HCV Clearance

Naglaa H. Shoukry, Ph.D., Associate Professor, Department of Medicine, University of Montreal, Canada

CD39 and CD103 Identify Tumor-reactive CD8 T-cells in Human Solid Tumors

Thomas Duhen, Ph.D., Senior Research Scientist, AgonOx

ANTI-TUMOR ANTIGEN ANTIBODIES IN CANCER IMMUNOTHERAPY

Tumor Targeting Antibodies: Distinct Innate and Adaptive Immune Sensing

Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, Mary Nell and Ralph B. Rogers Professorship in Immunology, UT Southwestern

Innate and Adaptive Integrin-targeted Combination Immunotherapy

Jennifer R. Cochran, Ph.D., Co-Founder and Director, Nodus Therapeutics

NK Cell Engagement with Bispecific Antibodies

Ann Cheung, Ph.D., Director of Biology, Dragonfly Therapeutics

Anti-chaperone Antibodies in Cancer Therapy    

Amy S. Lee, Ph.D., Associate Director for Basic Research, USC Norris Comprehensive Norris Cancer Center and Professor of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California

NOVEL THERAPEUTIC INDICATIONS FOR ANTIBODIES

Therapeutic Antibodies that Silence B Cells by Emulating Peripheral Immune Tolerance

John Cambier Ph.D., Distinguished Professor and Chair, Department of Immunology and Microbiology, University of Colorado SOM

Antibody Approaches to T1D

William Ridgway, Professor, University of Cincinnati

Action of Bispecific Anti-FGFR1/βKlotho Antibody in Obese Mice and Humans

Junichiro Sonoda, Ph.D., Senior Scientist, Cancer Immunology, Genentech

INNOVATING ANTIBODY THERAPEUTICS

Evolution of Antibodies of Different Germline Gene Origins Proceed through Different Paths

Mats Ohlin, Ph.D., Professor, Department of Immunotechnology & SciLifeLab, Lund University, Sweden

DNA-based Antibody Therapy via Antibody Gene Transfer

Kevin Hollevoet, Ph.D., Group Leader and Postdoc, Therapeutic and Diagnostic Antibodies, University of Leuven, Belgium

Structural Determinants for Modulating Antibody-Fc Receptor Interactions for Half-Life Enhancement and Effector Functions

Karthik Viswanathan, Ph.D., Director, Research, Visterra, Inc.